isarna-therapeutics.comHealthcareFounded: 1900Funding to Date: $131.24MM
Isarna Therapeutics is a clinical stage biotech company developing ISTH0036, a next-generation antisense to block TGF-beta 2 production, a key molecule in the pathogenesis of retinal disease.
View Enterprise Value for Isarna Therapeutics.